elvitegravir (GS 9137, EVG/c)
Jump to navigation
Jump to search
Indications
- treatment of HIV1 in combination with HIV medications that require boosting
- component of elvitegravir/emtricitabine/cobicistat/tenofovir (Quad)
Contraindications
Adverse effects
Laboratory
Mechanism of action
More general terms
Component of
References
- ↑ Wikipedia: Elvitegravir http://en.wikipedia.org/wiki/Elvitegravir
- ↑ 2.0 2.1 Zuger A Use of Antiretroviral Drugs in Pregnancy. Physician's First Watch, April 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. AIDSinfo. Clinical Guidelines Portal. March 28, 2014. http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (corresponding NGC guideline withdrawn March 2016) - ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ AIDSMAP: Elvitegravir http://www.aidsmap.com/Elvitegravir-GS-9137/page/1731274/